JY231 / Genocury Biotech - LARVOL DELTA

A single IV treatment retrains immune cells to fight autoimmune diseases in early trial (Medical Xpress) - "Sixteen patients who were resistant to standard treatments for their severe neurological and muscle autoimmune conditions each received a single IV infusion of the JY231 treatment. In every patient, JY231 successfully generated CAR-T cells inside the body. The newly trained cells multiplied, peaking 11 days after injection, and traveled throughout the body....The study included seven patients with progressive multiple sclerosis (MS), three with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD)..., three with generalized myasthenia gravis (gMG)..., and three with idiopathic inflammatory myopathies (IIM)."

Clinical data • Multiple Sclerosis • Myasthenia Gravis

JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia (clinicaltrials.gov) - P=N/A | N=20 | Recruiting | Sponsor: Affiliated Hospital of Guangdong Medical University | Not yet recruiting ➔ Recruiting

Enrollment open • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia (clinicaltrials.gov) - P=N/A | N=20 | Not yet recruiting | Sponsor: Affiliated Hospital of Guangdong Medical University

New trial • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

JY-CT-24-005: JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov) - P1/2 | N=20 | Recruiting | Sponsor: 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

New P1/2 trial • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

JY-CT-23-001: JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia (clinicaltrials.gov) - P=N/A | N=20 | Recruiting | Sponsor: Shenzhen Genocury Biotech Co., Ltd.

New trial • B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

JY231(JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia(B-ALL) (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

New P1 trial • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology

JY231 Injection in the Treatment of Relapsed or Refractory B-cell Lymphoma (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: Guangdong Second Provincial General Hospital

New P1 trial • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology